

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

**INFORMATION DISCLOSURE  
STATEMENT**

Docket Number:  
**52494/2102**

Application Number <b>Not Yet Assigned</b>	Filing Date <b>Filed Herewith</b>	Examiner <b>Not Yet Assigned</b>	Art Unit <b>Not Yet Assigned</b>
Invention Title <b>USE OF HUMAN SERUM RESISTANT VECTOR PARTICLES AND CELL LINES FOR HUMAN GENE THERAPY</b>		Inventor(s) <b>James M. Mason</b>	


Address to:

Mail Stop: Patent Application  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 35 U.S.C. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicants hereby bring the following references to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.
2. Copies of each patent, publications or other information listed on the modified PTO Form 1449 are not enclosed since they were previously cited by or submitted to the United States Patent Office in prior application Serial No. 09/040,103 which is relied upon for an earlier filing date under 35 U.S.C. 120.

Dated: March 1, 2004

By:

  
\_\_\_\_\_  
Lawrence P. Casson (Reg. No. 46,606)

KENYON & KENYON  
One Broadway  
New York, N.Y. 10004  
(212) 425-7200 (telephone)  
(212) 425-5288 (facsimile)  
CUSTOMER NO. 26646

**EXPRESS MAIL NO. EV 321889775 US**

NY01 666207 v 1

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	<b>ATTY. DOCKET NO.</b> <b>52494/2101</b>	<b>SERIAL NO.</b> <b>Not Yet Assigned</b>
	<b>APPLICANT</b> <b>James M. MASON</b>	
	<b>FILING DATE</b> <b>Herewith</b>	<b>GROUP</b> <b>Not Yet Assigned</b>

#### U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE*
	4,405,712	9/20/83	Vande Woude et al.			7/1/81
	5,562,904	10/8/96	Rother et al.			7/21/94
	5,576,201	11/19/96	Mason et al.			1/14/94
	5,580,766	12/3/96	Mason et al.			1/14/94
	5,643,770	7/1/97	Mason et al.			7/21/94
	5,871,997	2/16/99	Rother et al.			
	6,329,199 B1	12/2001	Pensiero et al.			

\* - If pertinent

#### FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO89/07150	8/10/89	PCT				
	WO92/07943	5/14/92	PCT				
	EP 0178,220	4/16/86	EPO				

#### OTHER DOCUMENTS

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
	Anderson et al., "Endogenous Origin of Defective Retroviruslike Particles from a Recombinant Chinese Hamster Ovary Cell Line," Virology, vol. 181, pp. 305-311 (1991).
	Anderson, Nature, 1998, Vol.392, pp. 25-30
	Chong & Vile, "Replication-Competent Retrovirus Produced by a 'Split-function' Third Generation Amphotropic Packaging Cell Line", Gene Ther., 3:624-629, 1996.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
	Cone & Mulligan, "High-efficiency Gene Transfer into Mammalian Cells: Generation of Helper-free Recombinant Retro Virus with Broad Mammalian Host Range", Proc. Nat'l. Acad. Sci. USA, 81:6349-6353, 1984.
	Cosset, et al., "High-titer Packaging Cells Producing Recombinant Retroviruses Resistant to Human Serum", J. Virol., 69:7430-7436, 1995.
	Crystal, "Transfer of Genes to Humans: Early Lessons and Obstacles to Success", Science, 270:404-410, 1995.
	Culver, et al., "In Vivo Gene Transfer with Retroviral Vector-producer Cells for Treatment of Experimental Brain Tumors", Science, 256:1550-1552, 1992.
	Eglitis, "Positive Selectable Markers for Use with Mammalian Cells in Culture", Hum. Gene Ther., 2:195-201, 1991.
	Eglitis & Anderson., "Retroviral Vectors for Introduction of Genes into Mammalian Cells", Biotechniques, 6:608-614, 1988.
	Fox, Nature Biotechnology, 2000, Vol. 18, pp. 143-144.
	Galili, et al., "Evolutionary Relationship Between the Natural Anti-gal Antibody and the Gal $\alpha$ -3gal Epitope in Primates", Proc. Nat'l. Acad. Sci. USA, 84:1369-1373, 1987.
	Gilboa, et al., "Transfer and Expression of Cloned Genes Using Retroviral Vectors", Biotechniques, 4:504-512, 1986.
	Girod, et al., "Homologous and Nonhomologous Retroviral Recombinations Are Both Involved in the Transfer by Infectious Particles of Defective Avian Leukosis Virus-derived Transcomplementing Genomes", J. Virol., 70:5651-5657, 1996.
	Hoshino, et al., "Human T-cell Leukemia Virus Is Not Used by Human Serum", Nature, 310:324-325, 1984.
	Kmiec, American Scientist, 1999, Vol. 87, pp. 240-247
	Lie et al., J. Virol., 1994, Vol. 68, No. 12, pp. 7840-7849.
	Mann, et al., "Construction of a Retrovirus Packaging Mutant and its Use to Produce Helper-free Defective Retrovirus", Cell, 33:153-159, 1983.
	Marshall, Science, 2003, Vol. 299, No. 5605, p. 320.
	Martinez & Dornberg, "Partial Reconstitution of a Replication-competent Retro Virus in Helper Cells with Partial Overlaps Between Vector and Helper Cell Genomes", Hum. Gene Ther., 7:705-712, 1996.
	Miller, "Human Gene Therapy Comes of Age", Nature, 357:455-460, 1992.
	Miller & Rosman, "Improved Retroviral Vectors for Gene Transfer and Expression", Biotechniques, 7:980-990, 1989.
	Morgenstern & Land, "Advanced Mammalian Gene Transfer: High Titre Retroviral Vectors with Multiple Drug Selection Markets and a Complementary Helper-free Packaging Cell Line", Nucleic Acids Res., 18:3587-3596, 1990.
	Mountain, TIBTECH, 2000, Vol. 18, pp. 119-128.
	Mulligan, "The Basic Science of Gene Therapy", Science, 260:926-932, 1993.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

EXAMINER INITIAL		AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
		Neethling, et al., "Protection of Pig Kidney (Pk15) Cells from the Cytotoxic Effect of Anti-pig Antibodies by A-galactosyl Oligosaccharides", Transplant; 57:959-963, 1994.
		Paillard, Human Gene Therapy, 1998, Vol. 9. pp. 767-768.
		Pensiero, et al., "Development of Amphotropic Murine Retrovirus Vectors Resistant to Inactivation by Human Serum", Hum. Gene Ther., 7:1095-1101, 1996.
		Rem, et al., "Toxicity Studies of Retro Viral-mediated Gene Transfer for the Treatment of Brain Tumors", J. Neurosurg., 79:400-407, 1993.
		Rollins, et al., "Retroviral Vector Producer Cell Killing in Human Serum Is Mediated by Natural Antibody and Complement: Strategies for Evading the Humoral Immune Response", Hum. Gene Ther., 7:619-626, 1996.
		Rother, et al., "Protection of Retroviral Vector Particles in Human Blood Through Complement Inhibition", Hum. Gene Ther., 6:429-435, 1995.
		Rother, et al., "A Novel of Retrovirus Inactivation in Human Serum Mediated by Anti- $\alpha$ -galactosyl Natural Antibody", J. Exp. Med., 182:1345-1355, 1995.
		Rother & Squinto, "The $\alpha$ -galactosyl Epitope: a Sugar Coating That Makes Viruses and Cells Unpalatable", Cell, 86:185-188, 1996.
		Russell, et al., "The Effects of Human Serum and Cerebrospinal Fluid on Retroviral Vectors and Packaging Cell Lines", Hum. Gene Ther., 6:635-641, 1995.
		Takeuchi, et al., "Sensitization of Cells and Retroviruses to Human Serum by ( $\alpha$ 1-3) Galactosyltransferase", Nature 379:85-88, 1996.
		Takeuchi, et al., "Sensitization of Rhabdo-, Lenti-, and Spumaviruses to Human Serum by Galactosyl ( $\alpha$ 1-3) Galactosylation", J. Virol., 71:6174-6178, August 1997.
		Takeuchi, et al., "Type C Retrovirus Inactivation by Human Complement Is Determined by Both the Viral Genome and the Producer Cell", J. Virol., 68:8001-8007, 1994.
		Verma et al., Nature, 1997, Vol. 389, pp. 239-242.
		Widner & Brundin, "Immunological Aspects of Grafting in the Mammalian Central Nervous System. A review and speculative synthesis", Brain Res. Rev., 13:287-324, 1988.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	